Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2022-12-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
第九届监事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Haiwang Bioengineering Co., Ltd. It details the convening and voting results of the Supervisory Board meeting, including approval of a proposal related to the controlling shareholder's non-competition commitment extension. The document is an official announcement of a board meeting decision, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a shareholder meeting material or voting result announcement from a general meeting. It fits best under Board/Management Information (MANG) as it relates to internal governance decisions and board resolutions.
2022-12-09 Chinese
第九届董事局第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including details about meeting attendance, voting results, and references to related announcements for shareholder meetings and capital increases. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is an announcement of board/management decisions and changes, specifically board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or regulatory filing. Confidence is high due to clear content and format.
2022-12-09 Chinese
关于公司控股股东避免同业竞争承诺延期的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the extension of a commitment made by its controlling shareholder, Shenzhen Haiwang Group Co., Ltd., to avoid competition within the same industry. It details the history of the commitment, the reasons for the extension, and the approval process by the board and supervisory committee. The document includes references to regulatory guidelines from the China Securities Regulatory Commission and discusses compliance and governance matters related to the controlling shareholder's commitments. There are no financial statements, earnings data, or audit information present. The document is an official announcement about a governance-related commitment extension rather than a full report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2022-12-09 Chinese
关于对河南海王医药集团有限公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the capital increase (增资) of a subsidiary company, 河南海王医药集团有限公司, by the parent company 深圳市海王生物工程股份有限公司. It details the background, financial data, purpose, and board approval of the capital increase. The document is relatively short (2814 characters) and focuses on a specific financing transaction rather than comprehensive financial results or reports. It does not contain full financial statements or detailed financial analysis typical of annual or interim reports. It is not a report publication announcement since it contains substantive information about the transaction itself. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-12-09 Chinese
独立董事关于第九届董事局第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting matter, specifically about the controlling shareholder's commitment extension to avoid competition. It references regulatory guidelines and company bylaws, and it is a formal opinion rather than a full report or announcement of voting results. It is related to board/management information as it concerns board meeting matters and independent directors' opinions. The document length is short and does not contain financial data or voting results, so it is not an Annual Report, Voting Results, or Regulatory Filing. Therefore, the best classification is Board/Management Information (MANG).
2022-12-09 Chinese
关于对外担保进展暨解除对外担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress and release of external guarantees. It details the company's guarantee obligations and their current status, including references to previous related announcements. The document is relatively short (728 characters) and focuses on a specific corporate update about guarantees, not a financial report or audit. It does not contain financial statements or detailed financial data. This type of announcement fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2022-12-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.